Trop2-targeted immunoPET Imaging of Solid Tumors

Summary

This study aims to establish and optimize the trophoblast cell surface antigen 2 (Trop2)-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging method and its physiological and pathological distribution characteristics, based on which the diagnostic efficacy of the above imaging agents in solid tumors (including uroepithelial cancer, bladder cancer, prostate cancer, lung cancer, nasopharyngeal cancer, liver cancer, cholangiocarcinoma, ovarian cancer, cervical cancer, endometrial cancer, thyroid cancer, head and neck cancer) will be evaluated.

Conditions

• Solid Tumor
• Solid Carcinoma
• Uroepithelial Carcinoma
• Bladder Cancer
• Prostate Cancer
• Lung Cancer
• Nasopharyngeal Cancer
• Liver Cancer
• Cholangiocarcinoma
• Ovarian Cancer
• Cervical Cancer
• Endometrial Cancer
• Thyroid Cancer
• Head and Neck Cancer

Interventions

DRUG

[18F]F-RESCA-RT4

Enrolled patients will receive 0.05-0.1 mCi/kg of \[18F\]F-RESCA-RT4. ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-RT4 injection.

DRUG

[68Ga]Ga-NOTA-T4

Enrolled patients will receive 0.05-0.1 mCi/kg of \[68Ga\]Ga-NOTA-T4. ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-T4 injection.

DRUG

[68Ga]Ga-NOTA-RT4

Enrolled patients will receive 0.05-0.1 mCi/kg of \[68Ga\]Ga-NOTA-RT4. ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-RT4 injection.

DRUG

[18F]F-RESCA-T4

Enrolled patients will receive 0.05-0.1 mCi/kg of \[18F\]F-RESCA-T4. ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-T4 injection.

Sponsors & Collaborators

• RenJi Hospital

  lead OTHER

Principal Investigators

• Jianjun Liu, Ph.D. & M.D. · Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University

• Weijun Wei, Ph.D. & M.D. · Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University

Study Design

Allocation

NA

Purpose

DIAGNOSTIC

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Max Age

75 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2024-12-23

Primary Completion

2027-12-31

Completion

2027-12-31

Countries

• China

Study Locations